Influence of the defective metabolism of sparteine on its pharmacokinetics.
Sparteine is metabolized by N1-oxidation, which in some subjects is defective. The defect has a pronounced effect on the kinetics of the drug. In nonmetabolisers elimination of sparteine proceeds entirely via renal excretion by a capacity-limited process, 99,9% of the dose being excreted as unchanged drug. In metabolisers the drug is mainly eliminated by metabolic degradation. Pronounced differences in beta-phase half-life and total plasma clearance were observed between metabolisers (156 min; 535 ml . min-1) and nonmetabolisers (409 min; 180 ml . min-1).
D000328:Adult; D001711:Biotransformation; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D013034:Sparteine / Q000097:blood / Q000378:metabolism*; D013997:Time Factors
D013034:Sparteine